SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. It is developing pre-clinical product application, SkinBiotix, a cosmetic cream for skin health, as well as for applications in infection control and eczema. The company was formerly known as Skinbiotix Ltd. SkinBioTherapeutics plc was founded in 2016 and is based in Macclesfield, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:SBTX
Previous Symbol
CUSIPN/A
Phone+44-161-4682760
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees6
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable
Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions
What is Skinbiotherapeutics' stock symbol?
Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."
Has Skinbiotherapeutics been receiving favorable news coverage?
Media stories about SBTX stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Skinbiotherapeutics earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term.
Who are some of Skinbiotherapeutics' key competitors?
Some companies that are related to Skinbiotherapeutics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Skinbiotherapeutics' key executives?
Skinbiotherapeutics' management team includes the folowing people:
- Dr. Catherine O'Neill, CEO & Director
- Mr. Douglas John Quinn, CFO, Company Sec. & Director
How do I buy shares of Skinbiotherapeutics?
Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Skinbiotherapeutics' stock price today?
One share of SBTX stock can currently be purchased for approximately GBX 13.50.
What is Skinbiotherapeutics' official website?
How can I contact Skinbiotherapeutics?
Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.
MarketBeat Community Rating for Skinbiotherapeutics (LON SBTX)
MarketBeat's community ratings are surveys of what our community members think about Skinbiotherapeutics and other stocks. Vote "Outperform" if you believe SBTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
